Have you Made a Difference to People With Epilepsy Through
Journalism? - Final Call for Entries to the 2012 Excellence in
Epilepsy Journalism Award
SLOUGH, England, November 12, 2012 /PRNewswire/ --
The International Bureau for Epilepsy and biopharmaceutical
company UCB today issued a final call for entries to the 2012
Excellence in Epilepsy Journalism Award. New entries will be
accepted until the final deadline, Friday 30th November.
To qualify, articles and broadcasts on epilepsy must be
published between 30th October
2011 and 30th November
2012.
"The award, now in its fourth year, aims to raise awareness
about epilepsy across the globe by recognising journalists who have
excelled in reporting on this often misunderstood condition.
By encouraging informative, original and responsible
journalism, the award hopes to raise awareness and decrease stigma
for the estimated 50 million people around the world living with
epilepsy,"[1] said Mike
Glynn, President of the IBE.
"Today, many people with epilepsy continue to face prejudice and
ignorance. Thought-provoking, responsible and accurate
journalism is important and the Excellence in Epilepsy Award is a
way of recognising journalists who produce compelling stories which
help everyone to understand the condition," commented Lode Dewulf,
Vice President, Patient Affairs, UCB.
The award is open to all journalists, across four categories -
print, online, broadcast TV and broadcast radio, with one winner to
be selected from each group. Entries can either be entered by the
author or via nomination by a third party. An independent
panel of media experts and people with experience of epilepsy will
judge submitted entries against set criteria to select winning
entries. The panel includes:
- Mr Robert Cole, Epilepsy
Association of South Australia and
the Northern Territory, Australia
- Dr Carlos Acevedo, Secretary
General of the International Bureau for Epilepsy and Editor,
International Epilepsy News, Chile
- Mr Joachim Mueller-Jung, Editor
and Journalist, Frankfurter Allgemeine Zeitung, Germany
- Mr David Josephs, Epilepsy
Advocate, UK
- Dr Mark Porter, GP & Medical
Correspondent for The Times, UK
- Mr Randolph Siegel, President,
Local Digital Strategy, Advance Publications, USA
- Mr Mike Glynn, President, IBE,
Ireland
"I am pleased to once again be part of the panel judging the
Excellence in Epilepsy Journalism Award," said Dr Mark Porter, "It's important that informative
and responsible reporting is encouraged to support both awareness
and understanding of epilepsy. Over the last three years I have
been impressed by the calibre of entries and look forward to
reviewing the 2012 entries."
For more information or to download an entry or nomination form,
please visit
http://www.ibe-epilepsy.org/announcing-the-excellence-in-journalism-awards-2012/
Notes to Editors
Entry Criteria
The four winners will receive travel
vouchers and will be encouraged to use them to fund travel for
future research or reporting on epilepsy.
To find out more information or to download an entry or
nomination form, please
visit: http://www.ibe-epilepsy.org/announcing-the-excellence-in-journalism-awards-2012/
Certain local restrictions may apply
regarding this award and the award is only available where not
prohibited or restricted by local laws and regulations.
References
-
http://www.who.int/mediacentre/factsheets/fs999/en/ [accessed
8th October 2012]
About the IBE
Founded more than 50 years ago, the IBE is an
organisation of laypersons and professionals interested in the
medical and non-medical aspects of epilepsy. The IBE addresses such
social problems as education, employment, insurance, driving
licence restrictions and public awareness, and supports its members
through a range of innovative and important initiatives aimed at
improving the quality of life of people with epilepsy and their
families. http://www.ibe-epilepsy.org
About UCB
UCB, Brussels, Belgium is a biopharmaceutical
company dedicated to the research, development and
commercialization of innovative medicines with a focus on the
fields of central nervous system and immunology disorders.
Forward looking statement
This press release contains
forward-looking statements based on current plans, estimates and
beliefs of management. Such statements are subject to risks and
uncertainties that may cause actual results to be materially
different from those that may be implied by such forward-looking
statements contained in this press release. Important factors that
could result in such differences include: changes in general
economic, business and competitive conditions, effects of future
judicial decisions, changes in regulation, exchange rate
fluctuations and hiring and retention of its employees.
October
2012: UK/12MIS0053b